8-K: Marker Therapeutics Reports Positive Clinical Trial Data and Secures NIH Funding

Marker Therapeutics announced encouraging preliminary results from its Phase 1 APOLLO study of MT-601 in lymphoma patients and secured a $2 million NIH grant.

Summary

• Marker Therapeutics reported its second quarter 2024 financial results and provided corporate updates.
• The company's lead program, MT-601, showed promising preliminary safety and efficacy in lymphoma patients in the Phase 1 APOLLO study, with three out of three participants showing objective responses.
• The treatment was well-tolerated with no observed cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS).
• Marker Therapeutics received a $2 million grant from the NIH to support the clinical investigation of MT-601 in lymphoma patients.
• An Investigational New Drug (IND) application was cleared by the FDA for MT-601 in combination with chemotherapy for metastatic pancreatic cancer, pending additional funding.
• The FDA also granted an IND for MT-401-OTS in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS), with clinical program initiation expected in the fourth quarter of 2024.
• The company's cash and cash equivalents were $7.8 million as of June 30, 2024, which is expected to fund operations into the fourth quarter of 2025.
• Research and development expenses were $2.3 million for the quarter ended June 30, 2024, compared to $2.4 million for the same period in 2023.
• General and administrative expenses were $1.1 million for the quarter ended June 30, 2024, compared to $2.5 million for the same period in 2023.
• The company reported a net loss from continuing operations of $2.2 million for the quarter ended June 30, 2024, compared to $4.1 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a significant grant award, indicating strong potential for the company. The financial results are mixed, but the overall tone is optimistic.

Positives

• The Phase 1 APOLLO study showed a 100% objective response rate in the initial three lymphoma patients treated with MT-601.
• MT-601 demonstrated a strong safety profile with no significant treatment-related adverse events.
• The $2 million NIH grant validates the potential of the APOLLO study and MT-601.
• The FDA clearance of the IND for MT-601 in pancreatic cancer expands the potential applications of the therapy.
• The FDA granting an IND for MT-401-OTS in AML and MDS provides another potential treatment option.
• The company's restructuring efforts have resulted in reduced operating expenses.
• The company's cash runway extends into the fourth quarter of 2025.

Negatives

• The company reported a net loss of $2.2 million for the quarter ended June 30, 2024.
• Clinical advancement of MT-601 for pancreatic cancer is pending additional financial support.
• The company's cash position is $7.8 million, which may require further funding in the future.

Risks

• The company's clinical programs are subject to the risks and uncertainties inherent in drug development.
• The company may need to raise additional capital to fund its operations and clinical trials.
• The company's success depends on the successful development and commercialization of its product candidates.
• There is no guarantee that the company's product candidates will be approved by regulatory authorities.
• The company faces competition from other companies developing cancer therapies.

Future Outlook

The company expects to provide a more comprehensive clinical update on the APOLLO study in the upcoming quarter and anticipates the clinical program initiation of MT-401-OTS during the fourth quarter of 2024.

Management Comments

• The second quarter of 2024 was characterized by ongoing momentum in our clinical programs, said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
• We are gratified by these preliminary results and expect to provide a more comprehensive clinical update on the APOLLO study in the upcoming quarter.
• We were pleased to receive this highly competitive grant, which reinforces the potential scientific merit and the capacity of the APOLLO study to address an unmet medical need.
• The financial performance in the past quarter demonstrates the benefits that we are seeing from our restructuring efforts that we initiated in the second quarter of 2023, including our agreement with Cell Ready, and the favorable impact that they are having on our business, especially our Operating Expenses.
• Unlike most small, pre-revenue companies in the Cell Therapy space, our extremely efficient structure, combined with our successful grant funding initiatives, are allowing us to maximize our cash runway and to focus the majority of our available funds on our clinical programs, concluded Dr. Vera.

Industry Context

The announcement highlights the growing interest and investment in T-cell based immunotherapies for cancer treatment, particularly in the context of relapsed or refractory hematological malignancies. The company's focus on non-genetically modified T-cells is a differentiating factor in the competitive landscape of cell therapies.

Comparison to Industry Standards

• The 100% objective response rate in the initial three patients in the APOLLO study is very promising compared to typical response rates in early-stage clinical trials for similar therapies.
• Companies like Kite Pharma and Novartis have achieved success with CAR-T cell therapies, but Marker's approach with multiTAA-specific T cells offers a potentially safer and more cost-effective alternative.
• The $2 million NIH grant is a significant validation of Marker's technology and its potential to address unmet medical needs, similar to other companies receiving government funding for innovative cancer therapies.
• The company's focus on non-dilutive funding is a strategic move to preserve shareholder value, which is a common practice among early-stage biotech companies.

Stakeholder Impact

• Shareholders may view the positive clinical trial results and NIH grant as positive developments.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients with lymphoma and other cancers may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue to enroll additional study participants in the Phase 1 APOLLO trial.
• The company expects to provide an update on safety and durability during the third quarter.
• The company anticipates the clinical program initiation of MT-401-OTS during the fourth quarter of 2024.

Key Dates

Keywords

Immunotherapy, T cell therapy, Lymphoma, MT-601, Pancreatic cancer, MT-401-OTS, AML, MDS, Clinical trial, NIH grant, FDA, Oncology